Key terms
About INMB
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INMB news
Apr 22
8:12am ET
INmune Bio raises $4.8M in gross proceeds through registered direct offering
Apr 12
1:35am ET
Inmune Bio’s INB03 Shows Promise as Pan-Immune Checkpoint Inhibitor: A Buy Rating from Analyst Joel Beatty
Apr 08
8:19am ET
INmune Bio presents data on INB03’s role as immune check point
Apr 02
4:10pm ET
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)
Mar 06
1:56pm ET
Buy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment Developments
Mar 05
8:11am ET
INmune Bio reports ‘significant’ EEG improvement in patients treated with Xpro
Feb 02
5:25am ET
BTIG Remains a Buy on Inmune Bio (INMB)
Feb 01
12:37am ET
Buy Rating Affirmed: Inmune Bio’s XPro Progresses with FDA’s Green Light and Unique Therapeutic Approach
Jan 31
12:35pm ET
Inmune Bio’s Buy Rating Affirmed Amid Positive Alzheimer’s Program Developments
Jan 30
8:05am ET
INmune Bio announces FDA removal of clinical hold for Alzheimer disease program
No recent press releases are available for INMB
INMB Financials
Key terms
Ad Feedback
INMB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INMB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range